BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Musso G, Bo S, Cassader M, De Michieli F, Gambino R. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr. 2013;98:895-906. [PMID: 23985808 DOI: 10.3945/ajcn.113.063792] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014;39:3-14. [DOI: 10.1111/apt.12543] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 7.2] [Reference Citation Analysis]
2 Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015;5:147-158. [PMID: 26155043 DOI: 10.1016/j.jceh.2015.02.002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
3 Kim YS, Lee SH, Park SG, Won BY, Chun H, Cho DY, Kim MJ, Lee JE, Haam JH, Han K. Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults. Metabolism 2020;103:154026. [PMID: 31765666 DOI: 10.1016/j.metabol.2019.154026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Engelking LJ, Cantoria MJ, Xu Y, Liang G. Developmental and extrahepatic physiological functions of SREBP pathway genes in mice. Semin Cell Dev Biol 2018;81:98-109. [PMID: 28736205 DOI: 10.1016/j.semcdb.2017.07.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wang Y, Zeng Z, Guan L, Ao R. GRHL2 induces liver fibrosis and intestinal mucosal barrier dysfunction in non-alcoholic fatty liver disease via microRNA-200 and the MAPK pathway. J Cell Mol Med 2020;24:6107-19. [PMID: 32324317 DOI: 10.1111/jcmm.15212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Flechtner-Mors M, George SN, Oeztuerk S, Haenle MM, Koenig W, Imhof A, Boehm BO, Graeter T, Mason RA, Kratzer W, Akinli AS; EMIL-Study group. Association of adiponectin with hepatic steatosis: a study of 1,349 subjects in a random population sample. BMC Res Notes 2014;7:207. [PMID: 24693952 DOI: 10.1186/1756-0500-7-207] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
7 Paschetta E, Belci P, Alisi A, Liccardo D, Cutrera R, Musso G, Nobili V. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm. 2015;2015:815721. [PMID: 25873773 DOI: 10.1155/2015/815721] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
8 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
9 Li XL, Sui JQ, Lu LL, Zhang NN, Xu X, Dong QY, Xin YN, Xuan SY. Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review. Lipids Health Dis. 2016;15:53. [PMID: 26965314 DOI: 10.1186/s12944-016-0221-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
10 Wang L, Wu S, Cai M, Ma J, Li S, Li M, Xu Y, Wei L, Shang J. Comprehensive Study of Multiple Stages Progressing to Nonalcoholic Steatohepatitis with Subsequent Fibrosis in SD Rats. Int J Mol Sci 2017;18:E1681. [PMID: 28820447 DOI: 10.3390/ijms18081681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Boutari C, Perakakis N, Mantzoros CS. Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul). 2018;33:33-43. [PMID: 29589386 DOI: 10.3803/enm.2018.33.1.33] [Cited by in Crossref: 61] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
12 Wood KL, Miller MH, Dillon JF. Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2015;2:e000019. [PMID: 26462272 DOI: 10.1136/bmjgast-2014-000019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
13 Green CJ, Pramfalk C, Morten KJ, Hodson L. From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations. Am J Physiol Endocrinol Metab 2015;308:E1-20. [PMID: 25352434 DOI: 10.1152/ajpendo.00192.2014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
14 Martínez-Montoro JI, Cornejo-Pareja I, Gómez-Pérez AM, Tinahones FJ. Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:4077. [PMID: 34836332 DOI: 10.3390/nu13114077] [Reference Citation Analysis]
15 Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016;65:1062-79. [DOI: 10.1016/j.metabol.2015.11.006] [Cited by in Crossref: 147] [Cited by in F6Publishing: 138] [Article Influence: 24.5] [Reference Citation Analysis]
16 Sonmez A, Nikolic D, Dogru T, Ercin CN, Genc H, Cesur M, Tapan S, Karslioğlu Y, Montalto G, Banach M, Toth PP, Bagci S, Rizzo M. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol 2015;9:576-82. [PMID: 26228676 DOI: 10.1016/j.jacl.2015.03.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
17 Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014;25:473-86. [PMID: 24802098 DOI: 10.1007/s00335-014-9521-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
18 Cremonini E, Daveri E, Iglesias DE, Kang J, Wang Z, Gray R, Mastaloudis A, Kay CD, Hester SN, Wood SM, Fraga CG, Oteiza PI. A randomized placebo-controlled cross-over study on the effects of anthocyanins on inflammatory and metabolic responses to a high-fat meal in healthy subjects. Redox Biology 2022;51:102273. [DOI: 10.1016/j.redox.2022.102273] [Reference Citation Analysis]
19 Peng XE, Chen FL, Liu W, Hu Z, Lin X. Lack of association between SREBF-1c gene polymorphisms and risk of non-alcoholic fatty liver disease in a Chinese Han population. Sci Rep 2016;6:32110. [PMID: 27572914 DOI: 10.1038/srep32110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis. Sci Rep. 2015;5:9284. [PMID: 25791171 DOI: 10.1038/srep09284] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 9.9] [Reference Citation Analysis]
21 Yousef MH, Al Juboori A, Albarrak AA, Ibdah JA, Tahan V. Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients. World J Gastrointest Pathophysiol 2017; 8(3): 100-107 [PMID: 28868179 DOI: 10.4291/wjgp.v8.i3.100] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
22 Sun DQ, Liu WY, Wu SJ, Zhu GQ, Braddock M, Zhang DC, Shi KQ, Song D, Zheng MH. Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. Oncotarget 2016;7:5728-37. [PMID: 26735337 DOI: 10.18632/oncotarget.6799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
23 Bosia M, Buonocore M, Bechi M, Santarelli L, Spangaro M, Cocchi F, Guglielmino C, Bianchi L, Bringheli S, Bosinelli F, Cavallaro R. Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome. Front Psychiatry 2018;9:647. [PMID: 30581395 DOI: 10.3389/fpsyt.2018.00647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
24 Liu JJ, Chen YY, Mo ZN, Tian GX, Tan AH, Gao Y, Yang XB, Zhang HY, Li ZX. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in adult males, South China. Int J Mol Sci 2013;14:19782-91. [PMID: 24084725 DOI: 10.3390/ijms141019782] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
25 Miranzadeh-Mahabadi H, Emadi-Baygi M, Nikpour P, Kelishadi R. Association Study Between Metabolic Syndrome and rs8066560 Polymorphism in the Promoter Region of Sterol Regulatory Element-binding Transcription Factor 1 Gene in Iranian Children and Adolescents. Int J Prev Med 2016;7:41. [PMID: 27076879 DOI: 10.4103/2008-7802.177314] [Reference Citation Analysis]
26 Han D, Chen J, Liu S, Zhang Z, Zhao Z, Jin W, Xin Y. Serum Resistin Levels in Adult Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. J Clin Transl Hepatol 2021;9:484-93. [PMID: 34447677 DOI: 10.14218/JCTH.2021.00018] [Reference Citation Analysis]
27 Lorbek G, Urlep Ž, Rozman D. Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease. Pharmacogenomics 2016;17:1273-88. [PMID: 27377717 DOI: 10.2217/pgs-2016-0047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
28 Li L, Liu D-, Yan H-, Wang Z-, Zhao S-, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies: Obesity and non-alcoholic fatty liver disease. Obesity Reviews 2016;17:510-9. [DOI: 10.1111/obr.12407] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 19.3] [Reference Citation Analysis]
29 Khalifa O, Errafii K, Al-Akl NS, Arredouani A. Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. Dis Markers 2020;2020:8822859. [PMID: 33133304 DOI: 10.1155/2020/8822859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
30 Willebrords J, Pereira IV, Maes M, Crespo Yanguas S, Colle I, Van Den Bossche B, Da Silva TC, de Oliveira CP, Andraus W, Alves VA. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res. 2015;59:106-125. [PMID: 26073454 DOI: 10.1016/j.plipres.2015.05.002] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 12.1] [Reference Citation Analysis]
31 Vargas-Alarcon G, Gonzalez-Pacheco H, Perez-Mendez O, Posadas-Sanchez R, Cardoso-Saldaña G, Ramirez-Bello J, Escobedo G, Nieto-Lima B, Fragoso JM. SREBF1c and SREBF2 gene polymorphisms are associated with acute coronary syndrome and blood lipid levels in Mexican population. PLoS One 2019;14:e0222017. [PMID: 31490983 DOI: 10.1371/journal.pone.0222017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wang AY, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clin Nutr. 2019;38:975-981. [PMID: 30466956 DOI: 10.1016/j.clnu.2018.08.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
33 Hu Y, Chen J, Yang L, Chen P, Li J, Chen L, Chen J, Huang X, Zhang Y, Bu S, Huang Q. The value of neck circumference (NC) as a predictor of non-alcoholic fatty liver disease (NAFLD). J Clin Transl Endocrinol 2014;1:133-9. [PMID: 29159094 DOI: 10.1016/j.jcte.2014.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
34 Saki S, Saki N, Poustchi H, Malekzadeh R. Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events. Middle East J Dig Dis 2020;12:65-88. [PMID: 32626560 DOI: 10.34172/mejdd.2020.166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]